1. Scrip
  2. >>Focus On Asia

TCMs Not Paxlovid Gain Traction As Beijing On High Alert

But WHO Cautious On Findings

 
• By Brian Yang

As Shanghai enters a second week of a city-wide lockdown with no signs of policy easing, officials are promoting the use of traditional Chinese medicines rather than Pfizer's recently approved Paxlovid.

China promotes TCM for COVID infections among surging cases in Shanghai and Jilin
SHANGHAI PROMOTES TCM FOR COVID INFECTIONS AS LOCKDOWNS PROLONGS • Source: Alamy

As Shanghai's 25 million residents face a strict extended lockdown but continue to log rising daily infections of COVID-19, China's capital city Beijing is also on edge, as reported cases increase and some neighborhoods face new restrictions.

Amid the higher cost of newly approved imported oral antivirals, the country is also turning to the use of traditional Chinese medicines (TCMs), pointing to a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.